298 related articles for article (PubMed ID: 26417884)
1. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
2. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
Kuo YC; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
[TBL] [Abstract][Full Text] [Related]
3. Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Liao CH; Wang CC; Jiang YH
Toxins (Basel); 2016 Mar; 8(4):91. PubMed ID: 27023603
[TBL] [Abstract][Full Text] [Related]
4. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
Hsiao SM; Lin HH; Kuo HC
PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB
Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
[TBL] [Abstract][Full Text] [Related]
9. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
Jiang YH; Kuo HC
Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder-neck dysfunction: objective and patient-reported outcomes.
Sacco E; Tienforti D; Bientinesi R; D'Addessi A; Racioppi M; Pinto F; Totaro A; Vittori M; D'Agostino D; Bassi P
Neurourol Urodyn; 2014 Jan; 33(1):142-6. PubMed ID: 23868794
[TBL] [Abstract][Full Text] [Related]
11. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
12. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.
Liao CH; Chen SF; Kuo HC
Neurourol Urodyn; 2016 Aug; 35(6):717-23. PubMed ID: 25914349
[TBL] [Abstract][Full Text] [Related]
13. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
Kuo HC; Liao CH; Chung SD
Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
15. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity.
Wang CC; Liao CH; Kuo HC
Neurourol Urodyn; 2014 Nov; 33(8):1235-9. PubMed ID: 24115083
[TBL] [Abstract][Full Text] [Related]
16. Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder.
Hsiao SM; Lin HH; Kuo HC
Sci Rep; 2017 Mar; 7():43753. PubMed ID: 28262756
[TBL] [Abstract][Full Text] [Related]
17. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M
Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
[TBL] [Abstract][Full Text] [Related]
19. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
Wang CC; Lee CL; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
